What does the Jardiance/EMPA-REG Outcome result mean for RVX-208? Not much. Keep in mind the Resverlogix's BETonMACE has a primary endpoint of 30% MACE reduction (combined endpoint of death, heart attack and stroke). EMPA-REG Outcome would have failed to achieve the 30% overall MACE reduction that RVX-208 will be aiming for.

Here's the highlight of the EMPA-REG outcome trial:

"Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company’s (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. In addition, treatment with JARDIANCE resulted in a lower risk of all-cause mortality (32 percent reduction) and hospitalization for heart failure (35 percent reduction)."

You can read the full press release here as well as a Street Insider article on it.

Best,

BearDownAZ